A Phase 3 interventional study of Ecnoglutide Low Dosage and Ecnoglutide Medium Dosage in Weight Management, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. — 7 open to participants now, 8 under way, 4 of them phase 3. Obesity · Hangzhou Sciwind Biosciences Co., Ltd..
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., this one has the largest enrollment, is the only one that started in 2023, is one of 5 in phase 3, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2023; this study’s year is marked. 1 started in 2023.
This study's enrollment of 664 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 152 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
4 of the studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07243171Hangzhou Sciwind Biosciences Co., Ltd.A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-01-05 |
| NCT07073417Hangzhou Sciwind Biosciences Co., Ltd.A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | 2027-02-27 |
| NCT07936058Hangzhou Sciwind Biosciences Co., Ltd.A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet | 2027-04-15 |
| NCT07929298Hangzhou Sciwind Biosciences Co., Ltd.A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Hangzhou Sciwind Biosciences Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
In this Phase 3 study, eligible participants will be randomized into three cohorts in a 3:1:3:1:3:1 ratio to receive once-weekly subcutaneous XW003 (low, medium, or high dosage) or volume-matching placebo for 48 weeks, including a dose-escalation period.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 664 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Within 3 months before screening, history of using the following drugs or treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
XW003 with low dosage once weekly
Drug: Ecnoglutide Low Dosage
Matched Placebo once weekly
Drug: Placebo
XW003 with medium dosage once weekly
Drug: Ecnoglutide Medium Dosage
Matched Placebo once weekly
Drug: Placebo
XW003 with high dosage once weekly
Drug: Ecnoglutide High Dosage
Matched Placebo once weekly
Drug: Placebo
Subcutaneous Injection
Also known as: XW003
Subcutaneous Injection
Also known as: XW003
Subcutaneous Injection
Also known as: XW003
Subcutaneous Injection with matched volume
Percent change in body weight from baseline
Time frame: Week 40
Proportion of subjects with weight loss ≥5% from baseline
Time frame: Week 40
Percent and absolute body weight change from baseline
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Proportion of subjects with weight loss ≥ 5%, 10%, 15% from baseline
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Change from baseline in BMI
height will be only measured at baseline
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Change from baseline in waist and hip circumferences
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40 and Week 48
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Jun 2024, 14 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 14 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.